<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553406</url>
  </required_header>
  <id_info>
    <org_study_id>SPR720-201</org_study_id>
    <nct_id>NCT04553406</nct_id>
  </id_info>
  <brief_title>Phase 2a Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease</brief_title>
  <official_title>A Randomized, Partially Blinded, Placebo- and Comparator-Controlled, Multicenter, Phase 2a, Dose Ranging, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SPR720 as Compared With Placebo or Standard of Care for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spero Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spero Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics (PK) of SPR719 generated from the orally (po) administered&#xD;
      SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease&#xD;
      (NTM-PD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision pending resolution of clinical hold with FDA&#xD;
  </why_stopped>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment Arms 1 to 3 are masked while Treatment Arm 4 is open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>From Day 1 to Day 28</time_frame>
    <description>For Treatment Arms 1, 2, and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>From Day 1 to Day 28</time_frame>
    <description>For Treatment Arms 1, 2, and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero to tau, where tau is the dosing interval (AUC0-tau),</measure>
    <time_frame>From Day 1 to Day 28</time_frame>
    <description>For Treatment Arms 1, 2, and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio of SPR719</measure>
    <time_frame>From Day 1 to Day 28</time_frame>
    <description>For Treatment Arms 1, 2, and 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reported adverse events (AEs)</measure>
    <time_frame>Day 1 to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically meaningful change in physical examination findings</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>To assess the incidents of abnormal body system assessments following 28 days of IP administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication usage</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>The type and frequency of medications used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory tests</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>To assess the incidents of abnormal hematology, biochemistry, coagulation and urinalysis assessments following 28 days of IP administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant (CS) out-of-normal range laboratory tests</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>To assess the incidents of clinically significant abnormal hematology, biochemistry, coagulation and urinalysis assessments following 28 days of IP administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shifts from baseline in selected laboratory tests using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 shift categories</measure>
    <time_frame>Day 1 to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vital sign measurements</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>To assess the incidents of abnormal heart rate, blood pressure and body temperature assessments following 28 days of IP administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>To assess the incidents of abnormal heart rate, cardiac rhythm, PR interval, RR interval, QRS interval, QT interval and QTC interval assessments following 28 days of IP administration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Mycobacterium Avium Complex</condition>
  <arm_group>
    <arm_group_label>SPR720 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPR720 500 mg (2 capsules of 250 mg SPR720 and 2 capsules of placebo) administered orally once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPR720 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPR720 1000 mg (4 capsules of 250 mg SPR720) administered orally once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules of placebo once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 500-1000 mg plus ethambutol HCl 15 mg/kg po once daily or Azithromycin 250-500 mg plus ethambutol HCl 15 mg/k po once daily. Optional rifampin 600 mg or rifabutin 300 mg po once daily may be added to the SOC regimen for up to 28 days.&#xD;
Additional SOC treatments may be considered in consultation with the medical monitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPR720</intervention_name>
    <description>250 mg capsules</description>
    <arm_group_label>SPR720 high dose</arm_group_label>
    <arm_group_label>SPR720 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 capsules of matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open-label SOC</intervention_name>
    <description>Clarithromycin 500-1000 mg plus ethambutol HCl 15 mg/kg po once daily or Azithromycin 250-500 mg plus ethambutol HCl 15 mg/k po once daily. Optional rifampin 600 mg or rifabutin 300 mg po once daily may be added to the SOC regimen for up to 28 days.&#xD;
Additional SOC treatments may be considered in consultation with the medical monitor.</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of NTM-PD due to MAC&#xD;
&#xD;
          -  Had at least 1 prior positive culture (sputum or bronchoalveolar lavage) positive for&#xD;
             MAC in the previous 6 months&#xD;
&#xD;
          -  Has an induced sputum culture at screening positive for MAC by at least one of the&#xD;
             following methods performed by the microbiology laboratory: quantitative culture on&#xD;
             solid agar or growth on liquid media (MGIT)&#xD;
&#xD;
          -  Is either treatment naïve and has not received any prior treatment for MAC, OR if&#xD;
             previously treated for MAC, has culture evidence of persistent, recurrent, or relapsed&#xD;
             disease and has been off therapy for at least 6 months&#xD;
&#xD;
          -  In the opinion of the Investigator, is ready to initiate treatment (treatment naïve)&#xD;
             or reinitiate treatment (previously treated) within the next 3 months, and for whom a&#xD;
             delay, in order to participate in a placebo-controlled clinical trial, is considered&#xD;
             reasonable and clinically acceptable&#xD;
&#xD;
          -  Had clinical signs and symptoms within the 6 weeks before the date of consent that are&#xD;
             consistent with NTM-PD with at least two of the following:&#xD;
&#xD;
               1. chronic cough&#xD;
&#xD;
               2. fatigue&#xD;
&#xD;
               3. frequent throat clearing&#xD;
&#xD;
               4. shortness of breath (dyspnea)&#xD;
&#xD;
               5. coughing up of blood (hemoptysis)&#xD;
&#xD;
               6. excessive mucus (sputum) production&#xD;
&#xD;
               7. fever&#xD;
&#xD;
               8. night sweats&#xD;
&#xD;
               9. loss of appetite&#xD;
&#xD;
              10. unintended weight loss&#xD;
&#xD;
              11. wheezing&#xD;
&#xD;
              12. chest pain&#xD;
&#xD;
          -  Has a measured forced expiratory volume in 1 second (% predicted FEV1) ≥30% on&#xD;
             pulmonary function test within 3 months prior to consent&#xD;
&#xD;
          -  Has a chest radiograph (CXR) or computed tomography (CT) scan within 6 months prior to&#xD;
             consent with findings consistent with NTM-PD. If no CXR or CT scan is available, a CXR&#xD;
             or CT scan should be performed at screening to confirm eligibility.&#xD;
&#xD;
          -  Other inclusion criteria per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has disseminated or extrapulmonary NTM&#xD;
&#xD;
          -  Has end-stage NTM-PD or treatment-refractory NTM-PD and is unlikely to respond to&#xD;
             protocol-specified SOC treatment&#xD;
&#xD;
          -  Had isolation on sputum cultures of any species of Mycobacterium other than a species&#xD;
             included in MAC within the past 6 months&#xD;
&#xD;
          -  Had prior isolation of MAC with macrolide resistance&#xD;
&#xD;
          -  Has received any systemic (oral or IV) or inhaled antibiotic with activity against MAC&#xD;
             between consent and randomization&#xD;
&#xD;
          -  Has a potentially confounding underlying pulmonary disease, including but not limited&#xD;
             to cystic fibrosis, active pulmonary malignancy (primary or metastatic),&#xD;
             NTM-hypersensitivity disease pneumoconiosis, or another advanced lung disease with a %&#xD;
             predicted FEV1&lt;30%&#xD;
&#xD;
          -  Other exclusion criteria per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Melnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spero Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

